Inhibition of SREBP1 has been reported to suppress the proliferation, invasion, and migration of lung cancer, prostate cancer, renal cell carcinoma, glioblastoma, and PC.31, 33, 45, 46, 47 Some researchers demonstrated that enhanced lipid synthesis facilitated gemcitabine resistance through endoplasmic reticulum stress.48 In this study, we found that knockdown of SREBP1 by siRNA inhibited the stemness of PC cells. Here, SREBF1 is linked to prostate carcinoma.